NCT01695941View on ClinicalTrials.gov

Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

May 29, 2018

Study Completion Date

March 19, 2026

Conditions
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Mantle Cell LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Mantle Cell Lymphoma
Interventions
DRUG

Alisertib

Given PO

DRUG

Bortezomib

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Rituximab

Given IV

Trial Locations (4)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

10461

Montefiore Medical Center-Einstein Campus, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH